Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||PIK3CA amp|
|Indication/Tumor Type||head and neck squamous cell carcinoma|
|Response Type||predicted - sensitive|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA amp||head and neck squamous cell carcinoma||predicted - sensitive||Rigosertib Sodium||Case Reports/Case Series||Actionable||In a Phase I trial, Rigosertib (ON 01910.Na) treatment resulted in a complete response with disappearance of mediastinal and lung disease in a patients with head and neck squamous cell carcinoma harboring PIK3CA amplification (Cancer Res April 15 2013 (73) (8 Supplement) LB-198).||detail...|
|PubMed Id||Reference Title||Details|
|Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors.||Full reference...|